QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hims--hers-health-inc-announces-mike-chi-elevated-to-chief-operating-officer-role

- SEC Filing

 hims--hers-powers-yieldmaxs-latest-options-based-income-etf

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option I...

 oscar-health-set-for-hims-style-moonshot-shorts-could-burn-as-aca-buzz-builds

Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies...

 hims--hers-eli-lilly-novo-nordisk-face-fda-scrutiny-what-it-means-for-weight-loss-etfs

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

 hims--hers-health-ceo-andrew-dudum-posts-on-x-around-100-fda-letters-went-out-last-week-to-companies-across-the-industry-as-part-of-the-administrations-recent-push-on-pharmaceutical-marketing-we-got-one-a-number-of-big-pharma-companies-received-themwe-have-a-long-history-of-working-with-regulators-to-keep-customers-safe-and-im-looking-forward-to-continuing-that-work-with-the-fda

https://x.com/andrewdudum/status/1968002019563905092?s=46&t=dtUiyC3dUs5yGRgT9qYHWg

 hims--hers-scrutinized-for-marketing-its-product-as-similar-to-ozempic-wegovy

FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps w...

 update-fda-warning-letter-to-hims--hers-health-was-originally-issued-on-september-9-2025

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-him...

 fda-issues-warning-letter-to-hims--hers-health

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-him...

 hims--hers-faces-fda-heat-as-commissioner-martin-makary-calls-out-super-bowl-ad-for-hiding-drug-risks

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs withou...

 canaccord-genuity-maintains-buy-on-hims--hers-health-maintains-68-price-target

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and maintains $68 price target.

 hims--hers-bets-on-hormonal-health-to-revive-investor-confidence

Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services ...

 bloomberg-reported-tuesday-hims-to-launch-new-offerings-for-men-with-low-testosterone

https://www.bloomberg.com/news/articles/2025-09-10/hims-to-launch-new-offerings-for-men-with-low-testosteron

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION